ESMO 2026 has ended. This guide stays up as the record of who was there. Next: ESMO 2027, Sep 17–21, 2027 in Barcelona
The Institute of Cancer Research at ESMO 2026
Oct 23–27, 2026 Madrid, Spain ~37k attendees Website
The Institute of Cancer Research takes part in 12 sessions at ESMO 2026 in Madrid. Its work explores targeted treatments and cancer biology, particularly in prostate cancer. It examines how genetic profiling can guide treatment for metastatic castration-resistant prostate cancer.
| Organization | ESMO 2026 Attendance |
|---|---|
The Institute of Cancer Research London, United Kingdom | |
Cancer research institute and college of the University of London, partnered with The Royal Marsden, a specialist cancer hospital in London. | Poster Fri Oct 23 13:00–15:00 Poster Fri Oct 23 15:15–16:00 Poster Fri Oct 23 15:15–16:00 Longitudinal plasma cell-free DNA (cfDNA) nucleosome footprints reveal transcriptional reprogramming during taxane treatment in metastatic castration-resistant prostate cancer (mCRPC) Genitourinary cancersBiomarkers & precision oncology Poster Fri Oct 23 15:15–16:00 PLA hyperplex proteomic profiling in mCRPC serial plasma samples Genitourinary cancersBiomarkers & precision oncology Poster Fri Oct 23 15:15–16:00 Targeted treatment of metastatic castrate-resistant prostate cancer based on genetic profiling: Results from the BARCODE2 trial Genitourinary cancersBiomarkers & precision oncology Poster Fri Oct 23 15:15–16:00 Satellite Fri Oct 23 18:35–18:45 Selecting your piece: CLDN18.2 targeted therapies Gastrointestinal cancers Satellite Fri Oct 23 18:55–19:10 The emerging picture: Precision medicine in clinical decision-making Gastrointestinal cancers Satellite Fri Oct 23 19:10–19:20 Every piece matters: Maximising patient outcomes Gastrointestinal cancers Satellite Fri Oct 23 19:20–19:40 The complete picture: Enhancing patient care Gastrointestinal cancers Chair Sat Oct 24 08:30–10:00 Talk Sat Oct 24 09:15–09:30 Anti-cancer vaccines: Technologies and clinical applications Gastrointestinal cancers Talk Sat Oct 24 15:25–15:45 Incorporation of PARP inhibitors Breast cancer Talk Sun Oct 25 11:00–11:15 Abstract Mon Oct 26 08:30–08:35 3717RO - Phase 3 peak crossover: Bezuclastinib + sunitinib combination following sunitinib monotherapy in patients with GIST Sarcoma, CNS, head & neck and rare cancers Talk Mon Oct 26 15:20–15:40 |
Find decision makers at The Institute of Cancer Research
Tell us what you sell and we’ll find the people at The Institute of Cancer Research most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Not affiliated with or endorsed by the European Society for Medical Oncology. Submit a correction